Clinical Trial Update: BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A BAFF/IL-17 bispecific antibody trial for Primary Sjogren's Syndrome has been withdrawn (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Snippet

Sponsor: Matthew C. Baker | Conditions: Primary Sjogren's Syndrome | Phase 2, Phase 3 | Status: WITHDRAWN